Abstract
Koumiss is a traditional fermented dairy product with health and medicinal benefits, particularly popular in the Inner Mongolia Autonomous Region of China. While it is known to regulate the gastrointestinal environment and enhance immunity, systematic reports on its specific immune-modulating effects have been scarce. This study identifies 21 bioactive components in Koumiss using LC-MS/MS and evaluates their therapeutic effects in an immunosuppressed rat model. Results demonstrate that Koumiss corrects organ atrophy, restores peripheral blood lymphocyte counts, and improves small intestinal mucosal structure, providing a scientific basis for its use as a therapeutic product.
Introduction
Koumiss, a traditional fermented horse milk, has been a cornerstone of Mongolian medicine for centuries. It is traditionally used to treat a variety of ailments, including tuberculosis, scurvy, and chronic digestive disorders. Despite its widespread use and anecdotal success, the underlying pharmacological mechanisms—especially regarding immune modulation—remain poorly understood. This study sought to characterize the chemical profile of Koumiss and validate its immune-restorative properties through computational and in vivo models.
Methodology
The researchers employed a multi-disciplinary approach to investigate the therapeutic potential of Koumiss:
- Chemical Characterization: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) was used to identify the product's composition. By leveraging software like Compound Discoverer and libraries like mzCloud and ChemSpider, 21 key bioactive components were identified.
- Molecular Docking: Computational modeling (AutoDock Vina) was used to predict the interaction between these 21 compounds and critical immune targets, including TNF, HLA-DRB1, FKBP1A, IL10, and IL2. Structures were retrieved from the Protein Data Bank (PDB) and PubChem.
- Animal Model Validation: A Sprague-Dawley rat model was used, with immunosuppression induced by Cyclophosphamide (CY), a chemotherapy drug known to cause leukopenia and organ atrophy. Rats were treated with varying doses of Koumiss to observe recovery in organ indices, hematological markers, and intestinal histology.
Key Findings
Chemical and Computational Insights
The identification of 21 specific compounds, such as L-Tryptophan and Linolenic acid, provides a concrete "chemical map" of Koumiss. Molecular docking revealed that most of these compounds possess strong binding affinities (≤ -5.0 kcal/mol) for immune-related proteins. Notably, Progesterone showed high affinity for IL2 and IL10, suggesting these pathways may be central to Koumiss’s therapeutic action.
Physiological Restoration
The in vivo trials yielded several significant results:
- Organ Recovery: Koumiss treatment significantly reversed the atrophy of the thymus and spleen, which are vital for immune cell maturation and surveillance.
- Hematological Improvement: There was a marked increase in White Blood Cell (WBC) counts and the CD4+/CD8+ T-cell ratio in treated rats compared to the immunosuppressed control group, suggesting a sophisticated modulation of the adaptive immune response.
- Intestinal Integrity: Koumiss effectively "rebuilt" the physical defense barrier of the gut. It increased the height of the intestinal villi and the number of Peyer’s patches—specialized lymphoid follicles essential for intestinal immune surveillance.
Conclusion and Future Directions
This study provides robust evidence that Koumiss acts as a potent immunomodulator. By restoring both the chemical signaling (cytokines and cell ratios) and the physical structure (intestinal mucosa) of the immune system, Koumiss offers a multi-faceted approach to treating immunosuppression.
While these results are promising, the authors acknowledge that future research should explore the role of the gut microbiome, as Koumiss is a probiotic-rich substance. Additionally, clinical trials are necessary to translate these findings from rat models to human therapeutic applications.
Summary updated